| 000 | 01969nam a2200253Ia 4500 | ||
|---|---|---|---|
| 003 | MX-MdCICY | ||
| 005 | 20250625153924.0 | ||
| 040 | _cCICY | ||
| 090 | _aB-13511 | ||
| 245 | 1 | 0 | _aLeishmaniasis: focus on the design of nanoparticulate vaccine delivery systems |
| 490 | 0 | _vExpert Rev. Vaccines, 11(1), p.69-86, 2012 | |
| 520 | 3 | _aAlthough mass vaccination of the entire population of an endemic area would be the most cost-effective tool to diminish Leishmania burden, an effective vaccine is not yet commercially available. Practically, vaccines have failed to achieve the required level of protection, possibly owing to the lack of an appropriate adjuvant and/or delivery system. Therefore, there is still an imperative demand for an improved, safe and efficient delivery system to enhance the immunogenicity of available vaccine candidates. Nanoparticles are proficient in boosting the quality and magnitude of immune responses in a predictable fashion. Herein, we discuss how nanoparticulate vaccine delivery systems can be used to induce appropriate immune responses against leishmaniasis by controlling physicochemical properties of the vaccine. Stability, production reproducibility, low cost per dose and low risk-benefit ratios are desirable characteristics of an ideal vaccine formulation and solid lipid nanoparticles may serve as one of the most promising practical strategies to help to achieve such a leishmanial vaccine, at least in canine species in the developing world. | |
| 650 | 1 | 4 | _aADJUVANT |
| 650 | 1 | 4 | _aDELIVERY SYSTEM |
| 650 | 1 | 4 | _aLEISHMANIASI |
| 650 | 1 | 4 | _aNANOPARTICLE |
| 650 | 1 | 4 | _aSOLID LIPID NANOPARTICLE |
| 650 | 1 | 4 | _aVACCINATION |
| 700 | 1 | 2 | _aDelaram Doroud |
| 700 | 1 | 2 | _aSima Rafati |
| 856 | 4 | 0 |
_uhttps://drive.google.com/file/d/1v2FvoTybDkbWwudbbk4hJj5V_YvrQVF3/view?usp=drivesdk _zPara ver el documento ingresa a Google con tu cuenta: @cicy.edu.mx |
| 942 |
_2Loc _cREF1 |
||
| 008 | 250602s9999 xx |||||s2 |||| ||und|d | ||
| 999 |
_c47710 _d47710 |
||